Copyright Reports & Markets. All rights reserved.

Global Bipolar Disorder Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Bipolar Disorder Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Selective Serotonin Reuptake Inhibitor
      • 1.4.3 Serotonin Norepinephrine Reuptake Inhibitors
      • 1.4.4 Tricyclic Antidepressants
      • 1.4.5 Monoamine Oxidase Inhibitors
      • 1.4.6 Benzodiazepines
      • 1.4.7 Beta Blockers
    • 1.5 Market by Application
      • 1.5.1 Global Bipolar Disorder Market Share by Application (2014-2025)
      • 1.5.2 Mood Stabilizers
      • 1.5.3 Anticonvulsants
      • 1.5.4 Antipsychotic drugs
      • 1.5.5 Antidepressant drugs
      • 1.5.6 Antianxiety drugs
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Bipolar Disorder Market Size
    • 2.2 Bipolar Disorder Growth Trends by Regions
      • 2.2.1 Bipolar Disorder Market Size by Regions (2014-2025)
      • 2.2.2 Bipolar Disorder Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Bipolar Disorder Market Size by Manufacturers
      • 3.1.1 Global Bipolar Disorder Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Bipolar Disorder Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Bipolar Disorder Market Concentration Ratio (CR5 and HHI)
    • 3.2 Bipolar Disorder Key Players Head office and Area Served
    • 3.3 Key Players Bipolar Disorder Product/Solution/Service
    • 3.4 Date of Enter into Bipolar Disorder Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Bipolar Disorder Market Size by Type (2014-2019)
    • 4.2 Global Bipolar Disorder Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Bipolar Disorder Market Size (2014-2019)
    • 5.2 Bipolar Disorder Key Players in United States
    • 5.3 United States Bipolar Disorder Market Size by Type
    • 5.4 United States Bipolar Disorder Market Size by Application

    6 Europe

    • 6.1 Europe Bipolar Disorder Market Size (2014-2019)
    • 6.2 Bipolar Disorder Key Players in Europe
    • 6.3 Europe Bipolar Disorder Market Size by Type
    • 6.4 Europe Bipolar Disorder Market Size by Application

    7 China

    • 7.1 China Bipolar Disorder Market Size (2014-2019)
    • 7.2 Bipolar Disorder Key Players in China
    • 7.3 China Bipolar Disorder Market Size by Type
    • 7.4 China Bipolar Disorder Market Size by Application

    8 Japan

    • 8.1 Japan Bipolar Disorder Market Size (2014-2019)
    • 8.2 Bipolar Disorder Key Players in Japan
    • 8.3 Japan Bipolar Disorder Market Size by Type
    • 8.4 Japan Bipolar Disorder Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Bipolar Disorder Market Size (2014-2019)
    • 9.2 Bipolar Disorder Key Players in Southeast Asia
    • 9.3 Southeast Asia Bipolar Disorder Market Size by Type
    • 9.4 Southeast Asia Bipolar Disorder Market Size by Application

    10 India

    • 10.1 India Bipolar Disorder Market Size (2014-2019)
    • 10.2 Bipolar Disorder Key Players in India
    • 10.3 India Bipolar Disorder Market Size by Type
    • 10.4 India Bipolar Disorder Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Bipolar Disorder Market Size (2014-2019)
    • 11.2 Bipolar Disorder Key Players in Central & South America
    • 11.3 Central & South America Bipolar Disorder Market Size by Type
    • 11.4 Central & South America Bipolar Disorder Market Size by Application

    12 International Players Profiles

    • 12.1 Glaxo SmithKline (GSK)
      • 12.1.1 Glaxo SmithKline (GSK) Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Bipolar Disorder Introduction
      • 12.1.4 Glaxo SmithKline (GSK) Revenue in Bipolar Disorder Business (2014-2019)
      • 12.1.5 Glaxo SmithKline (GSK) Recent Development
    • 12.2 Pfizer
      • 12.2.1 Pfizer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Bipolar Disorder Introduction
      • 12.2.4 Pfizer Revenue in Bipolar Disorder Business (2014-2019)
      • 12.2.5 Pfizer Recent Development
    • 12.3 Janssen Pharmaceuticals
      • 12.3.1 Janssen Pharmaceuticals Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Bipolar Disorder Introduction
      • 12.3.4 Janssen Pharmaceuticals Revenue in Bipolar Disorder Business (2014-2019)
      • 12.3.5 Janssen Pharmaceuticals Recent Development
    • 12.4 Eli Lilly
      • 12.4.1 Eli Lilly Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Bipolar Disorder Introduction
      • 12.4.4 Eli Lilly Revenue in Bipolar Disorder Business (2014-2019)
      • 12.4.5 Eli Lilly Recent Development
    • 12.5 Allergan
      • 12.5.1 Allergan Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Bipolar Disorder Introduction
      • 12.5.4 Allergan Revenue in Bipolar Disorder Business (2014-2019)
      • 12.5.5 Allergan Recent Development
    • 12.6 Novartis
      • 12.6.1 Novartis Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Bipolar Disorder Introduction
      • 12.6.4 Novartis Revenue in Bipolar Disorder Business (2014-2019)
      • 12.6.5 Novartis Recent Development
    • 12.7 AbbVie
      • 12.7.1 AbbVie Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Bipolar Disorder Introduction
      • 12.7.4 AbbVie Revenue in Bipolar Disorder Business (2014-2019)
      • 12.7.5 AbbVie Recent Development
    • 12.8 Otsuka
      • 12.8.1 Otsuka Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Bipolar Disorder Introduction
      • 12.8.4 Otsuka Revenue in Bipolar Disorder Business (2014-2019)
      • 12.8.5 Otsuka Recent Development
    • 12.9 AstraZeneca
      • 12.9.1 AstraZeneca Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Bipolar Disorder Introduction
      • 12.9.4 AstraZeneca Revenue in Bipolar Disorder Business (2014-2019)
      • 12.9.5 AstraZeneca Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. There are four basic types of bipolar disorder; all of them involve clear changes in mood, energy, and activity levels.
      People suffering with bipolar disorder have intense emotional states that occur in distinct periods called mood episodes. Mood episode is characterized by drastic changes in person’s usual mood and their behavior. Mood episode is mainly classified into two main types: manic episodes and depressive episodes. An overexcited or joyful state is called a manic episode and an extremely hopeless or sad state is called a depressive episode. Sometimes, a mood episode includes symptoms of both depression and mania, known as mixed state. These mood episodes hamper school and job performance.
      In 2018, the global Bipolar Disorder market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Bipolar Disorder status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bipolar Disorder development in United States, Europe and China.

      The key players covered in this study
      Glaxo SmithKline (GSK)
      Pfizer
      Janssen Pharmaceuticals
      Eli Lilly
      Allergan
      Novartis
      AbbVie
      Otsuka
      AstraZeneca

      Market segment by Type, the product can be split into
      Selective Serotonin Reuptake Inhibitor
      Serotonin Norepinephrine Reuptake Inhibitors
      Tricyclic Antidepressants
      Monoamine Oxidase Inhibitors
      Benzodiazepines
      Beta Blockers

      Market segment by Application, split into
      Mood Stabilizers
      Anticonvulsants
      Antipsychotic drugs
      Antidepressant drugs
      Antianxiety drugs

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Bipolar Disorder status, future forecast, growth opportunity, key market and key players.
      To present the Bipolar Disorder development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Bipolar Disorder are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now